Bevacizumab alone or with chemotherapy in highly pretreated, relapsed, epithelial ovarian cancer patients.

e15590 Background: To evaluate the safety and efficacy of bevacizumab (BEV) alone or combined with chemotherapy (CT) in a compassive use program sponsored by the Spanish Ovarian Cancer Research Gro...